glp 1 shortage guidance Societies take stand against off-brand GLP-1s over safety concerns Prioritizing Health | Diabetes, Diet

Tirzepatide is a dual agonist targeting both GLP-1 and GIP receptors, improving insulin sensitivity and promoting fullness, leading to superior weight losssome patients lose over 20%, with an average of 15%

By 2024, 7% of people with obesity were prescribed these drugs, and the rate has continued to increase

Storing it sealed and cold minimizes this risk

Bayl Univ Med Cent Proc

NICE CG189 and BOMSS guidelines advise that patients should receive structured monitoring for a minimum of two years post-surgery through a specialist bariatric service, with ongoing annual reviews thereafter ideally shared between the bariatric team and the patient's GP

Lalanne et al., 2016, 2018)